← Back to Search

AKI Follow-up Clinic for Chronic Kidney Disease (FUSION Trial)

N/A

Waitlist Available

Led By Ron Wald, MDCM, MPH

Research Sponsored by Unity Health Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years post-randomization

Awards & highlights

FUSION Trial Summary

This trial is looking at whether or not a follow-up clinic for people who have had a kidney injury can help reduce the chance of further kidney problems.

Eligible Conditions

Chronic Kidney Disease
Acute Kidney Injury

FUSION Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years post-randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years post-randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years post-randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Change in quality-of-life as measured by EuroQol-5D-5L instrument

Number of acute kidney injury episodes post-randomization using KDIGO serum creatinine criteria

Proportion deceased

+15 more

FUSION Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: AKI Follow-up ClinicExperimental Treatment1 Intervention

Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit

Group II: Usual CareActive Control1 Intervention

Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.

Do I qualify?Apply below to find out